Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM | Managing infectious complications of CAR-T therapy

Nirali Shah • 15 Oct 2021
COSTEM
General CAR-T

Nirali Shah, MD, National Cancer Institute, National Institutes of Health, Bethesda, MD, talks on the management of the infectious complications of chimeric antigen receptor T-cell (CAR-T) therapies targeting different antigens, commenting on implications for clinical practice. This interview took place at the 6th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), which took place virtually.

More from Nirali Shah

Next steps for improving dual CARs
1:31
Next steps for improving dual CARs
Nirali Shah • 15 Oct 2021
The future role of CAR-T in pediatric ALL
1:23
The future role of CAR-T in pediatric ALL
Nirali Shah • 15 Oct 2021
Prior blinatumomab use impacts CD19-CAR T-cell therapy response rates in R/R ALL
3:42
Prior blinatumomab use impacts CD19-CAR T-cell therapy response rates in R/R ALL
Nirali Shah • 25 Nov 2020
Anti-CD22 CAR T-cell therapy for ALL: trial update, utility for salvage and CD19 status
1:21
Anti-CD22 CAR T-cell therapy for ALL: trial update, utility for salvage and CD19 status
Nirali Shah • 9 Dec 2017

Related Videos

The ethical challenges of AI in hematology: patient communication, trust and regulation
3:12
The ethical challenges of AI in hematology: patient communication, trust and regulation
Adrián Mosquera Orgueira • 24 Sep 2026
The future of AI in hematology: personalized medicine, opportunities and risks
2:30
The future of AI in hematology: personalized medicine, opportunities and risks
Adrián Mosquera Orgueira • 24 Sep 2026
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
5:18
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
Shyam Patel • 13 Oct 2026
The scientific and clinical implications of therapy-related CHIP in oncology
2:43
The scientific and clinical implications of therapy-related CHIP in oncology
Shyam Patel • 13 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals